biotech investing Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
biotech investing Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
biotech investing Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
biotech investing At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
biotech investing Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
biotech investing Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
biotech investing Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
biotech investing Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
biotech investing Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
CoTec Holdings Corp. Announces Partial Settlement and Amendment and Restatement of Convertible Loan Facilities
Westport to Showcase High?Pressure CNG Fuel System for North American Heavy?Duty Fleets at ACT Expo 2026
